As liver biopsy remains the only standard for clinically diagnosing NAFLD/NASH (Bedossa, 2018), some investigations indicate changes in serum ALT and AST levels may be unreliable for the diagnosis and monitoring of the disease (Filozof et al., 2015). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.